Literature DB >> 11313004

Molecular virology of Epstein-Barr virus.

G W Bornkamm1, W Hammerschmidt.   

Abstract

Epstein-Barr virus (EBV) interacts with its host in three distinct ways in a highly regulated fashion: (i) EBV infects human B lymphocytes and induces proliferation of the infected cells, (ii) it enters into a latent phase in vivo that follows the proliferative phase, and (iii) it can be reactivated giving rise to the production of infectious progeny for reinfection of cells of the same type or transmission of the virus to another individual. In healthy people, these processes take place simultaneously in different anatomical and functional compartments and are linked to each other in a highly dynamic steady-state equilibrium. The development of a genetic system has paved the way for the dissection of those processes at a molecular level that can be studied in vitro, i.e. B-cell immortalization and the lytic cycle leading to production of infectious progeny. Polymerase chain reaction analyses coupled to fluorescent-activated cell sorting has on the other hand allowed a descriptive analysis of the virus-host interaction in peripheral blood cells as well as in tonsillar B cells in vivo. This paper is aimed at compiling our present knowledge on the process of B-cell immortalization in vitro as well as in vivo latency, and attempts to integrate this knowledge into the framework of the viral life cycle in vivo.

Entities:  

Mesh:

Year:  2001        PMID: 11313004      PMCID: PMC1088437          DOI: 10.1098/rstb.2000.0781

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  312 in total

1.  Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.

Authors:  S A Radkov; M Bain; P J Farrell; M West; M Rowe; M J Allday
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Multiple functions within the Epstein-Barr virus EBNA-3A protein.

Authors:  I Cludts; P J Farrell
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity.

Authors:  H Kataoka; H Tahara; T Watanabe; M Sugawara; T Ide; M Goto; Y Furuichi; M Sugimoto
Journal:  Differentiation       Date:  1997-12       Impact factor: 3.880

4.  Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation.

Authors:  A Altmeyer; R C Simmons; S Krajewski; J C Reed; G W Bornkamm; S Chen-Kiang
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

5.  Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation.

Authors:  J E Floettmann; M Rowe
Journal:  Oncogene       Date:  1997-10-09       Impact factor: 9.867

6.  Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.

Authors:  A Carbone; G Gaidano; A Gloghini; L M Larocca; D Capello; V Canzonieri; A Antinori; U Tirelli; B Falini; R Dalla-Favera
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

7.  Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

Authors:  O Gires; U Zimber-Strobl; R Gonnella; M Ueffing; G Marschall; R Zeidler; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

8.  The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB.

Authors:  K M Izumi; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

9.  Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade.

Authors:  A Kieser; E Kilger; O Gires; M Ueffing; W Kolch; W Hammerschmidt
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

10.  Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.

Authors:  E Kilger; A Kieser; M Baumann; W Hammerschmidt
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

View more
  54 in total

1.  Gammaherpesvirus lytic gene expression as characterized by DNA array.

Authors:  Joo Wook Ahn; Kenneth L Powell; Paul Kellam; Dagmar G Alber
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Epstein-Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein.

Authors:  Stephanie Barth; Michael Liss; Marc D Voss; Thomas Dobner; Utz Fischer; Gunter Meister; Friedrich A Grässer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

4.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes.

Authors:  Elena Kashuba; Mariya Yurchenko; Surya Pavan Yenamandra; Boris Snopok; Maria Isaguliants; Laszlo Szekely; George Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

6.  Asymmetric Arginine dimethylation of Epstein-Barr virus nuclear antigen 2 promotes DNA targeting.

Authors:  Henrik Gross; Stephanie Barth; Richard D Palermo; Alfredo Mamiani; Christine Hennard; Ursula Zimber-Strobl; Michelle J West; Elisabeth Kremmer; Friedrich A Grässer
Journal:  Virology       Date:  2009-12-06       Impact factor: 3.616

7.  Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma.

Authors:  Hee Jong Shin; Do Nyun Kim; Suk Kyeong Lee
Journal:  Mol Cells       Date:  2011-05-27       Impact factor: 5.034

8.  Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes.

Authors:  S Y Baik; H S Yun; H J Lee; M H Lee; S E Jung; J W Kim; J P Jeon; Y K Shin; H S Rhee; K C Kimm; B G Han
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

9.  Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population.

Authors:  Margaret Conacher; Robin Callard; Karen McAulay; Helen Chapel; David Webster; Dinakantha Kumararatne; Anita Chandra; Gavin Spickett; Paul A Hopwood; Dorothy H Crawford
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Rhesus lymphocryptovirus type 1-associated B-cell nasal lymphoma in SIV-infected rhesus macaques.

Authors:  A K Marr-Belvin; A K Carville; M A Fahey; K Boisvert; S A Klumpp; M Ohashi; F Wang; S P O'Neil; S V Westmoreland
Journal:  Vet Pathol       Date:  2008-11       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.